<DOC>
	<DOCNO>NCT01086254</DOCNO>
	<brief_summary>Primary Objective : - ass objective response rate ( ORR ) Iniparib ( SAR240550 ) administer 60-min intravenous infusion twice weekly , combine gemcitabine/cisplatin chemotherapy regimen ( GCS ) well standard regimen gemcitabine/cisplatin ( GC ) patient stage IV non small cell lung cancer . Secondary objective : - ass safety profile study combination GCS standard regimen GC ; - ass progression free survival overall survival arm ; - ass relationship DNA repair pathway characteristic tumor baseline clinical outcome disease . - assess effect Iniparib PAR level peripheral blood mononuclear cell ( PBMC ) . ( As 10 September 2010 , collection PBMC temporarily discontinue . )</brief_summary>
	<brief_title>SAR240550 Combination With Gemcitabine/Cisplatin Non-small Cell Lung Cancer</brief_title>
	<detailed_description>The duration study patient include period inclusion 3 week . The patient may continue treatment maximum 6 cycle disease progression , unacceptable toxicity consent withdrawal , follow minimum 30-day follow-up last study treatment administration . Patients follow least 30 day last administration study treatment safety purpose . In case study treatment discontinuation without disease progression , efficacy data collect every 6 week disease progression , death end study whatever come first . After disease progression , patient followed-up every 12 week ( 3 month ) overall survival ( OS ) death end study whatever come first . The end study one year first dose last treated patient .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Iniparib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Inclusion criterion : Stage IV disease ( include stage IIIB pleural effusion ) prior systemic therapy . Adjuvant therapy allow end 1 year inclusion study . Histologically confirm squamous cell bronchogenic carcinoma OR non squamous cell carcinoma . Patients previous radiotherapy definitive therapy locally advance nonsmall cell lung cancer eligible , long select measurable lesion outside original radiation therapy port . Radiation therapy must complete &gt; 4 week prior study entry . Palliative radiotherapy must complete &gt; 2 week prior study entry . Irradiated lesion may serve measurable lesion . At least one measurable lesion accord Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 . Adequate bone marrow reserve . Adequate liver renal function . Women childbearing potential must negative serum urine pregnancy test perform within 7 day prior start treatment . Exclusion criterion : Prior treatment gemcitabine , platinum salt PARP inhibitor class compound . Past current history neoplasm entry diagnosis , exception treat nonmelanoma skin cancer carcinoma insitu cervix , cancer cure local therapy alone expect diseasefree survival &gt; = 5 year . Major medical condition might affect study participation e.g . cardiac disease , uncontrolled infection ( &gt; Grade 2 ) . Presence active brain metastasis . A major surgical procedure , open biopsy , significant traumatic injury within 28 day begin treatment , anticipation need major surgery course study . Any history medical psychiatric condition laboratory abnormality , opinion investigator , may increase risk associate study participation administration investigational product , may interfere interpretation result Grade 2 high ear labyrinth disorder . Known suspect allergy/hypersensitivity agent give course trial . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>